Duality Biotherapeutics' (HKG:9606) board has approved a proposal to issue yuan-denominated shares and seek a listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, according to an Oct. 17 Hong Kong bourse filing.
Shares of the biopharmaceutical firm gained nearly 5% in morning trade Monday.
The proposed A-share issue remains subject to market conditions, board and shareholder approval, and clearance from Chinese regulators, the company said.
No application has yet been made to the authorities, and details such as the timing and size of the offering have not been finalized, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.